Cornerstone Advisors (Washington)’s United Therapeutics UTHR Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-18	Closed	-$1K	–	1346
2019 Q2	$1K	Sell	18 -10	-36%	-$935	﹤0.01%	1411
2019 Q1	$3K	Buy	28 +15	+115%	+$1.75K	﹤0.01%	948
2018 Q4	$1K	Hold	13	–	–	﹤0.01%	1111
2018 Q3	$2K	Hold	13	–	–	﹤0.01%	914
2018 Q2	$1K	Buy	13 +4	+44%	+$440	﹤0.01%	1119
2018 Q1	$1K	Buy	+9	New	+$1.14K	﹤0.01%	1102
2016 Q3	–	Sell	-140	Closed	-$15K	–	934
2016 Q2	$15K	Sell	140 -17	-11%	-$1.9K	0.02%	344
2016 Q1	$17K	Buy	157 +17	+12%	+$2.15K	0.02%	315
2015 Q4	$22K	Hold	140	–	–	0.02%	302
2015 Q3	$18K	Buy	+140	New	+$22.5K	0.02%	343

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cornerstone Advisors (Washington)'s UTHR Position: Q3 2019 in Review

Cornerstone Advisors (Washington) sold out of United Therapeutics (UTHR) in Q3 2019, closing a stake of 18 shares — an estimated $1K sold.

Cornerstone Advisors (Washington) first reported a position in UTHR in Q3 2015 and held it in 10 quarters. The position peaked at $22K in Q4 2015. 302 funds tracked by Wall St. Rank hold UTHR as of Q3 2019.

Cornerstone Advisors (Washington) reported no remaining United Therapeutics position as of Q3 2019 after selling out during the quarter.
Cornerstone Advisors (Washington) sold 18 United Therapeutics shares in Q3 2019, an estimated $1K.
Cornerstone Advisors (Washington) first reported a position in United Therapeutics in Q3 2015 and held it in 10 quarters.
Cornerstone Advisors (Washington)'s United Therapeutics position peaked at $22K in Q4 2015.
302 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2019.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2019, filed 23 Oct 2019.